Replimune Group (REPL)
(Real Time Quote from BATS)
$7.68 USD
-0.69 (-8.19%)
Updated Jun 17, 2024 12:16 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
Replimune Group, Inc. [REPL]
Reports for Purchase
Showing records 121 - 140 ( 193 total )
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
SITC Abstracts Detail RP2 Responses; RP1 Data Improvement: Increasing PT to $46
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
SITC Abstracts Indicate Opportunity in Solid Tumors
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare -Strategies and Therapeutic Opportunities to Address Checkpoint (IO) Resistance
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Fiscal Q1; Multiple RP1 Cohorts on Track; First Look at RP2 Around the Corner
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Stock Price Appreciation Presents Profit-Taking Point; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
RP1 + Opdivo Update Encouraging; FY2020 Financials; Raising PT to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Interim Data Highly Supportive of Registration-Directed Studies; Fiscal Q4
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Register for Our Webinar: ACSO Abstract Titles Review '-' April 30th at 10am ET
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T